Revon Media
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us
No Result
View All Result
Revon Media
No Result
View All Result

Trial for malaria vaccine

Trial for malaria vaccine
Share on FacebookShare on Twitter

BioNTech SE (BioNTech) announced on Dec 23, 2022, the initiation of a first-in-human Phase 1 study with BNT165b1, the first candidate from the Company’s BNT165 program, to develop a multi-antigen malaria vaccine candidate.

BioNTech will initially evaluate a set of mRNA-encoded antigens of the malaria-causing parasite Plasmodium falciparum (P. falciparum) to help select the multi-antigen vaccine candidate to proceed to planned later-stage trials.

This first clinical trial (NCT05581641) will evaluate the safety, tolerability and exploratory immunogenicity of the vaccine candidate BNT165b1. BNT165b1 expresses certain parts of the circumsporozoite protein (CSP).

The World Health Organisation (WHO) estimated that there were over 247 million cases of malaria and 619,000 associated deaths in 2021. P. falciparum caused the majority of deaths in sub-Saharan Africa. Ninety-five per cent of all cases occurred in the African region with children under five years old being the most vulnerable population, due to a high risk of severe disease progression and chronic complications.

So far, one vaccine has been approved in children for prevention of a malaria infection. There is still medical need for the development and manufacturing of highly efficacious vaccines preventing malaria caused by P. falciparum to achieve the goal of malaria eradication and to reduce the physical and socioeconomic burden of malaria in highly endemic areas.

BioNTech’s proprietary BNT165 program is part of the Company’s Malaria project first announced in July 2021 and has two key objectives:

First, to develop a well-tolerated and highly effective mRNA vaccine with durable protective immunity to prevent blood-stage Malaria infection, clinical disease and disease-associated mortality as well as reduction of secondary transmissions.

The second objective is to develop sustainable vaccine production and supply solutions on the African continent, including the Company’s BioNTainer solution which aims to contribute to WHO and the Africa Centers for Disease Control and Prevention’s (Africa CDC) mission to promote health and strengthen the capacity of the region to detect, prevent, control and respond quickly and effectively to disease threats. – The Health

Tags: BioNTechForeign NewsMalaria vaccineThe Health 2023The Health Jan/Feb 2023theHealth
Previous Post

Moderna to acquire OriCiro Genomics

Next Post

Organ damage risk for lupus patients

Live Edition Paper

NOV 2020 ePaper

OCT 2020 ePaper


 

Subscribe for free complimentary live editions:

Recent News

  • Harrison.ai raises US$97m, partners Sonic Healthcare
    February 7, 2022
    On Dec 1, 2021, Harrison.ai, a groundbreaking healthcare AI company, announced […]
  • Optometry in the eye healthcare system
    December 19, 2022
    Transforming and bringing together the optometry industry under a single […]
  • Duopharma scores a first with halal-certified cancer treatment
    March 16, 2023
    Duopharma Biotech Berhad recorded a new milestone when it became the first […]
  • Investing in vaccine self-sufficiency
    March 1, 2021
    Manufacturing the vaccine in Malaysia can be done through an adaptable […]
  • Prohibited health and cosmetic products seized
    January 1, 2021
    THE Pharmacy Enforcement Division, Ministry of Health Malaysia (MoH) together […]

Connect

Office

Revon Media Sdn Bhd
A member of Revongen Corporation
Headquarters
Revongen Corporation Center,
Level 17, Top Glove Tower, No.16,
Persiaran Setia Dagang,Setia Alam,
Seksyen U13, 40170 Shah Alam,
Selangor Darul Ehsan, Malaysia.

Contact

Tel: +603 3359 1166
Fax: +6 03 3358 0303

Copyright © 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd. About Us | Contact Us | Privacy Policy | Terms of use

No Result
View All Result
  • Newspaper
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Live Edition
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • Media
    • theHealth
    • @Halal
    • @green
    • @Pancing
    • myHealth
  • About Us
  • Contact Us

© 2021 Revon Media Sdn Bhd. A publication of Revon Media Sdn Bhd

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist